# Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

> **NCT03053635** · PHASE1 · COMPLETED · sponsor: **Theralase® Technologies Inc.** · enrollment: 6 (actual)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG

## Interventions

- **DRUG:** TLD1433 infusion and photodynamic therapy (PDT) treatment

## Key facts

- **NCT ID:** NCT03053635
- **Lead sponsor:** Theralase® Technologies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-21
- **Primary completion:** 2018-08-09
- **Final completion:** 2018-08-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053635, "Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03053635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*